ClinicalTrials.gg
RecruitingNCT07748468Updated Nov 19, 2026

Impact of Antioxidant-rich Supplementation on Skin Carotenoids Status, Antioxidant Status and Cardiometabolic Health in Overweight and Obese Individuals

An interventional study of Antioxidant-rich supplementation Element and Antioxidant-rich supplementation Optimal in Overweight , Obesity and Antioxidant Status, sponsored by National University of Singapore. Recruiting at 2 sites in Singapore. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National University of Singapore · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 19, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Obesity with a site in Singapore — 17 open to participants now, 25 under way, 1 of them phase 3. Obesity · Singapore.

Planned enrollment
31st of 68
83 · median 70
Started
2026
with 8 others
No phase
44 of 83
9 open now
Primary completion
2027-08
later than 17 of 24 live
Registered
77th of 83
by date
Lead sponsor
6 of 83
National University of Singapore

Among the 83 studies in Obesity with a site in Singapore, this one is the 31st largest by planned enrollment of the 68 interventional ones that give a count, is one of 9 that started in 2026, is one of 44 with no phase, reaches primary completion later than 17 of the 24 other live ones, and was the 77th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

17 of the 83 studies in Obesity with a site in Singapore are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Obesity with a site in Singapore, or all of them as a file.
02

Study summary

This study aims to evaluate the effects of antioxidant-rich supplementation on skin carotenoid status, antioxidant status, and cardiometabolic health in overweight and obese individuals. The study may provide additional scientific evidence to support the further refinement of current dietary and nutritional recommendations.

Read the detailed description

This study will be a single-blind, randomized, parallel-group trial, and all participants will complete a 12-week study period. A total of 66 participants will be recruited and randomly assigned to continue their habitual diet with or without antioxidant-rich supplementation. This study aims to investigate whether antioxidant-rich supplementation will influence body composition, skin carotenoid status, antioxidant status, and cardiometabolic health. The study will comprise 1 screening visit and 4 test visits.

03

Conditions studied

  • Overweight , Obesity
  • Antioxidant Status

Browse trials for

Keywords

  • Overweight
  • Obese
  • Antioxidants
  • Long-term
  • Body composition
  • Cardiometabolic health
  • Skin carotenoid
04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 83 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

National University of Singapore is the lead sponsor of 212 studies on the registry; 50 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to give (AMT score ≥ 8 for older adults [65-70 years old])
  • Adults 21-70 years old
  • English-literate
  • Have venous access sufficient to allow for blood sampling as per the protocol
  • No drastic change of diet for the past 1 year
  • If taking medication, has been consistently taking antihypertensive/cholesterol-lowering/type-2 diabetic medication for more than 3 years prior to starting the study

Exclusion criteria

Exclusion Criteria:

  • Weight change > 3kg in the past 3 months
  • Exercising vigorously over the past 3 months
  • Taking medications or dietary supplements which may impact eye/skin health
  • Taking lipid-lowering and blood pressure controlling medications less than 3 years
  • Smoking
  • Drinking more than 2 alcoholic drinks per day
  • Pregnant, lactating, or planning pregnancy in the next 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
83 participants (estimated)

Study arms

  • No intervention
    Control

    Maintained habitual diet without receving the intervention.

  • Experimental
    LifePak Elements Supplementation

    Consume the LifePak (Elements) every day for 12 weeks.

    Dietary Supplement: Antioxidant-rich supplementation Element

  • Experimental
    LifePak Optimal Supplementation

    Consume the LifePak (Optimal) every day for 12 weeks.

    Dietary Supplement: Antioxidant-rich supplementation Optimal

Interventions

  • Dietary supplementAntioxidant-rich supplementation Element

    Maintained habitual diet with additionally taking LifePak Element for 12 weeks

  • Dietary supplementAntioxidant-rich supplementation Optimal

    Maintaining habitual diet with additionally taking LifePak Optimal for 12 weeks

07

What researchers measure

Primary outcomes

  1. Change in Skin Carotenoid Score Measured by Prysm iO™ from Baseline to Week 12

    Skin carotenoid status will be assessed using the Prysm iO™ device. The device scans the participant's fingertip and provides a skin carotenoid score, also referred to as the Prysm Score. Results will be reported as the numerical Prysm Score. Higher scores indicate higher skin carotenoid levels.

    Time frame: Week 0, 4, 8, 12

  2. Mean Change from Baseline in Blood Carotenoid Concentration

    Blood carotenoid concentration will be assessed using blood samples collected from participants. Results will be reported as the mean change from baseline in blood carotenoid concentration at Week 12. Higher concentrations indicate higher circulating carotenoid status.

    Time frame: Week 0 and Week 12

Secondary outcomes

  1. Mean Change from Baseline in Total Antioxidant Capacity in Blood Samples

    Total antioxidant capacity will be assessed using blood samples collected from participants. Results will be reported as the mean change from baseline in total antioxidant capacity at each post-baseline time point.

    Time frame: Week 0 and Week 12

  2. Mean Change from Baseline in Fasting Blood Lipid and Lipoprotein Concentrations

    Fasting blood lipid and lipoprotein concentrations will be assessed using blood samples collected from participants after an overnight fast. The lipid and lipoprotein profile may include total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. Results will be reported as the mean change from baseline in each lipid and lipoprotein parameter at Week 12.

    Time frame: Week 0 and Week 12

  3. Mean Change from Baseline in Fasting Blood Glucose Concentration

    Fasting blood glucose concentration will be assessed using blood samples collected from participants after an overnight fast. Results will be reported as the mean change from baseline in fasting blood glucose concentration at Week 12.

    Time frame: Week 0 and Week 12

  4. Mean Change from Baseline in Fasting Blood Insulin Concentration

    Fasting blood insulin concentration will be assessed using blood samples collected from participants after an overnight fast. Results will be reported as the mean change from baseline in fasting blood insulin concentration at Week 12.

    Time frame: Week 0 and Week 12

  5. Mean Change from Baseline in Blood Biomarkers of Oxidative Stress: Malondialdehyde and 8-Isoprostane

    Oxidative stress will be assessed using blood samples collected from participants. Blood biomarkers of oxidative stress will include malondialdehyde and 8-isoprostane. Results will be reported as the mean change from baseline in malondialdehyde concentration and 8-isoprostane concentration at Week 12. Higher concentrations indicate higher levels of oxidative stress.

    Time frame: Week 0 and Week 12

  6. Mean Change from Baseline in Skin Autofluorescence Measured by AGE Reader mu Connect

    Skin advanced glycation end product accumulation will be assessed non-invasively using the AGE Reader mu Connect. The device measures skin tissue autofluorescence on the inside of the participant's dominant lower forearm. Results will be reported as the mean change from baseline in AGE Reader measurement result, expressed in arbitrary units. Higher values indicate higher skin advanced glycation end product accumulation.

    Time frame: Week 0, 4, 8, 12

  7. Mean Change from Baseline in Blood Advanced Glycation End Product Level

    Blood advanced glycation end product level will be assessed using blood samples collected from participants. Results will be reported as the mean change from baseline in blood advanced glycation end product level at Week 12.

    Time frame: Week 0 and Week 12

  8. Mean change from baseline in anthropometric and body composition parameters

    Anthropometric and body composition parameters will be assessed using standard measurements and InBody body composition analysis. Parameters may include body weight, waist circumference, body fat percentage, fat mass, fat-free mass, skeletal muscle mass and body mass index. Results will be reported as the mean change from baseline at each post-baseline time point.

    Time frame: Week 0, 4, 8, 12

Other outcomes

  1. Mean Change from Baseline in Blood Clock Gene-Related Markers

    Clock gene-related markers will be assessed using blood samples collected from participants. Results will be reported as the mean change from baseline in selected clock gene-related markers at Week 12. This outcome is exploratory and will be used to explore potential biological changes associated with the intervention.

    Time frame: Week 0 and Week 12

08

Study locations

1 of 2 sites recruiting
  • Food Science and Technology
    Singapore, Singapore 117550, Singapore
    Recruiting
  • NUS, Department of Food Science and Technology, 1 Science Drive 3, Block S13, #03-07, Singapore, 117550
    Singapore, 117542, Singapore
    Not yet recruiting
    • Lingyin Yu, B.Sc. · Contacte1124962@u.nus.edu · (+65) 8942 1809
    • Jung Eun Kim, Ph.D., R.D. · Principal investigator
09

References and documents

Individual participant data

Plan to share: No — Electronic copies of the data with identifiable participant information will be kept on NUS OneDrive with access limited only Dr Kim Jung Eun and her research staff. All data will be de-identified prior to statistical analyses.

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 11 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
Aug 5, 2026
StartActual
Aug 28, 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
1 site added. NUS, Department of Food Science and Technology, 1 Science Drive 3, Block S13, #03-07, Singapore, 117550 is now Not yet recruiting
Show site
  • Food Science and Technology · Singapore, Singapore
Nov 19, 2026
Start date
Aug 15, 2026→Aug 28, 2026 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    1 site added. NUS, Department of Food Science and Technology, 1 Science Drive 3, Block S13, #03-07, Singapore, 117550 is now Not yet recruiting
    Show site
    • Food Science and Technology · Singapore, Singapore
    Start date Aug 15, 2026→Aug 28, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07748468
Collaborators
Nu Skin Enterprises
Responsible party
Jung Eun Kim (Assistant Professor, National University of Singapore) — Principal investigator
First posted
Aug 5, 2026
Start date
Aug 28, 2026
Primary completion
Aug 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Lingyin Yu, B.Sc.
Contact
e1124962@u.nus.edu
(+65) 8942 1809
Jung Eun Kim, Ph.D., R.D.
principal investigator · National University of Singapore, Department of Food Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion